1354223-46-3

Basic information

• Product Name: 3-bromo-7-iodoquinoline
• Synonyms: 3-bromo-7-iodoquinoline
• CAS NO: 1354223-46-3
• Molecular Formula: C9H5BrIN
• Molecular Weight: 333.95117
• EINECS: -0
• Mol File: 1354223-46-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 356.3±22.0 °C(Predicted)
• Appearance: /
• Density: 2.154±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 1.01±0.25(Predicted)
• CAS DataBase Reference: 3-bromo-7-iodoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-7-iodoquinoline(1354223-46-3)
• EPA Substance Registry System: 3-bromo-7-iodoquinoline(1354223-46-3)

Safety Data

• Hazardous Substances Data: 1354223-46-3(Hazardous Substances Data)

Usage

General Description

3-bromo-7-iodoquinoline is a chemical compound that belongs to the class of organic compounds known as quinolines and derivatives. It is characterized by a quinoline moiety which is a heterocyclic aromatic ring system derived from pyridine and benzene. In 3-bromo-7-iodoquinoline, the quinoline ring is substituted at positions 3 and 7 with bromine and iodine atoms respectively. It is produced for research and scientific experimentation purposes, typically used in the synthesis of other organic compounds. The compound is usually handled and stored in a dry and well-ventilated area due to its highly reactive nature. Detailed information regarding its physical and chemical properties such as molar mass, melting point, boiling point, and density may vary based on the database and should be confirmed from a reliable source. Given its reactive nature, appropriate safety measures are necessary when handling and disposing of this compound.

Upstream product

• 613-51-4 7-nitroquinoline 
• 1344046-07-6 7-amino-3-bromoquinoline 
• 30450-62-5 7-nitro-1,2,3,4-tetrahydro-quinoline 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The present disclosure describes novel heterocyclic PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.